Direct Healthcare Professional communication: Two strengths of Insulin degludec (Tresiba) on UK market

Source: Novo Nordisk Area: News Insulin degludec (Tresiba) has recently been launched in the UK in two strengths: 100 units/mL and 200 units/mL. The latter strength is higher than that of other existing insulin products available in the UK. Tresiba comes in the form of two distinct pen devices which have been designed to clearly differentiate between the two strengths.   Novo Nordisk has issued this letter to minimise the risk of medication errors when prescribing Tresiba. It contains the following recommendations:   . Ensure that the strength of Tresiba is included on the prescription.   . Dose conversion is not necessary if transferring a patient to a new strength as the dose counter window in the pen shows the number of units that will be injected regardless of strength.   . Pharmacists must ensure that the correct strength is dispensed and if in doubt, contact the prescriber.   . Pharmacists must ask patients to visually identify the ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news